Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Weight Management in Pediatric Prader-Willi Syndrome
NCT02527200Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Peptides
- Countries
- 8
01
Overview
A Phase 3 trial of liraglutide in Prader-Willi syndrome (PWS), obesity, sponsored by Novo Nordisk. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
Prader-Willi syndrome (PWS)obesity
Beyond the preview
Go deeper on NCT02527200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527200.